Marwan Fakih

Sep 9, 2024 | digitalcommons.library.tmc.edu | Yasutoshi Kuboki |Marwan Fakih |John Strickler |Rona Yaeger

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance.

Jun 27, 2024 | onclive.com | Marwan Fakih

CommentaryVideoJune 27, 2024Author(s):Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer. Marwan G.

Jun 13, 2024 | nature.com | Andrea Bullock |Benjamin L. Schlechter |Marwan Fakih |Joseph E. Grossman |Rachel E. Sanborn |Bruno Bockorny | +3 more

AbstractMicrosatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study.

Oct 23, 2023 | healio.com | Mark Leiser |Mindy Valcarcel |Marwan Fakih |Miriam Koopman

You've successfully added Hematology Oncology: Gastrointestinal Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Sotorasib plus panitumumab extended PFS compared with standard care. Grade 3 or higher adverse events occurred less frequently with the combination.

Sep 12, 2023 | onclive.com | Marwan Fakih

Marwan G. Fakih, MD, Judy & Bernard Briskin distinguished director, Clinical Research, associate director, Clinical Research, codirector, Gastrointestinal Cancer Program, medical director, Judy & Bernard Briskin Center for Clinical Research, City of Hope, expands on long-term findings from the phase 2/3 PROSPECT trial (NCT01515787), and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.